What Does the Published Research Say About 5‑Amino‑1MQ?

Research Context

• Topic focus: 5‑Amino‑1‑methylquinolinium (5‑Amino‑1MQ) appears in this packet as a chemical entity with a registry listing and a patent‑search record. The PubChem entry is a registry record (not functional validation) [pubchem:950107]. The patent‑search record indicates filings that propose 5‑Amino‑1MQ as an NNMT inhibitor scaffold; patents are not clinical evidence [patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].
• Evidence composition: human observational/biomarker studies related to NNMT in disease contexts, review literature on NNMT biology and translational interest, and preclinical reports on NNMT inhibition and structure–activity relationships (SAR) [pubmed:39067875; pubmed:37576910; pubmed:34029690; pubmed:33453420; pubmed:35756670; pubmed:32389809; pubmed:40484359; pubmed:41543936; pubmed:37523719; pubmed:29320176; pubmed:36622754; pubmed:31589440].
• Scope note: the packet does not include human interventional trials of 5‑Amino‑1MQ or other NNMT inhibitors. Where human data are present, they are disease‑specific, observational, and focus on NNMT rather than on 5‑Amino‑1MQ per se.

Key Takeaway

Published studies in this packet do not include human trials of 5‑Amino‑1MQ. Human data relate to NNMT as a disease‑associated biomarker (UBC, CKD), while NNMT inhibition evidence is limited to animal and cell models. Registry and patent listings do not establish clinical efficacy or safety.

Direct Answer

• No human clinical trials of 5‑Amino‑1MQ are reported in the supplied literature. Human findings address NNMT associations in specific diseases (urothelial bladder cancer; chronic kidney disease) and should not be generalized as therapeutic efficacy [pubmed:39067875; pubmed:37576910].
• NNMT inhibition has been studied preclinically (animal and cell models) across cardiac, liver, kidney, and oncology‑relevant contexts; these are not established human outcomes [pubmed:40484359; pubmed:32389809; pubmed:41543936; pubmed:36622754].
• The packet provides a chemical registry entry and patent‑search context for 5‑Amino‑1MQ but no human dosing, safety, or efficacy data [pubchem:950107; patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].

Human evidence (observational/associational; not interventional)

• Urothelial bladder cancer (UBC): NNMT in cancer‑associated fibroblasts is linked to tumor progression and resistance to immunotherapy, with mechanistic work alongside analyses in human UBC cohorts [pubmed:39067875].
• Chronic kidney disease (CKD): NNMT is reported as a predictive marker of tubular fibrosis in human CKD cohorts [pubmed:37576910].
• Interpretation boundaries: These studies inform NNMT’s disease associations and potential biomarker roles. They do not establish therapeutic benefit of NNMT inhibition or of 5‑Amino‑1MQ in humans [pubmed:39067875; pubmed:37576910].

Review context (mechanistic framing; not a substitute for outcomes)

• Reviews summarize NNMT’s catalytic role (methylation of nicotinamide to 1‑methylnicotinamide), its intersections with cellular metabolism and epigenetic regulation, and its potential as a biomarker/target across diseases [pubmed:34029690; pubmed:33453420; pubmed:35756670]. Mechanistic plausibility does not establish clinical utility.

Preclinical evidence and chemical tools (non‑human)

• Liver/metabolism: ER stress–induced NNMT upregulation contributes to alcohol‑related fatty liver development in preclinical models [pubmed:32389809].
• Cardiac (mouse): NNMT inhibition improved cardiac structure and function in a heart‑failure‑with‑preserved‑ejection‑fraction mouse model [pubmed:40484359].
• Kidney (non‑human): NNMT inhibition counteracted tubular senescence and fibrosis in early‑stage CKD models [pubmed:41543936].
• Oncology/mechanisms (preclinical systems): m6A RNA modifications regulated chemotherapy response via NNMT [pubmed:36622754].
• Chemical probes/SAR: discovery and optimization of NNMT bisubstrate and high‑affinity inhibitors, including cell‑potent tools, define tractable scaffolds and structure–activity relationships; these published inhibitor series are distinct from 5‑Amino‑1MQ and should not be cross‑extrapolated [pubmed:29320176; pubmed:31589440; pubmed:37523719].
• Translation note: Animal/cell findings and chemical‑tool potency are not evidence of human clinical benefit or safety [pubmed:32389809; pubmed:40484359; pubmed:41543936; pubmed:29320176; pubmed:31589440; pubmed:37523719; pubmed:36622754].

Chemical identity and patent context for 5‑Amino‑1MQ

• Chemical registry: 5‑Amino‑1‑methylquinolinium is indexed in PubChem as a compound record; the listing itself does not validate function or therapeutic use [pubchem:950107].
• Intellectual property: A patent‑search record lists filings/applications that propose 5‑Amino‑1MQ as an NNMT inhibitor scaffold. Such records signal research interest but do not substitute for peer‑reviewed human efficacy or safety data [patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].

Limitations and open questions from this packet

• No human interventional data for 5‑Amino‑1MQ or any NNMT inhibitor are presented.
• Human findings are disease‑specific observational/biomarker associations (UBC; CKD) and should not be extrapolated to other conditions without new data [pubmed:39067875; pubmed:37576910].
• Dosing, safety, and generalized risk profiles in humans are not addressed by this packet.
• A substantial share of the evidence is preclinical, limiting translational certainty.

FAQ

• Is 5‑Amino‑1MQ clinically studied in humans?
• No human clinical trials of 5‑Amino‑1MQ are included in the supplied literature. The packet provides only a registry entry and a patent‑search record for this compound [pubchem:950107; patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].
• What human evidence exists around NNMT?
• Observational studies link NNMT to tumor progression and immunotherapy resistance in urothelial bladder cancer and identify NNMT as a predictive marker of tubular fibrosis in CKD; these are not intervention trials and do not demonstrate therapeutic benefit [pubmed:39067875; pubmed:37576910].
• What do animal and cell studies suggest about NNMT inhibition?
• NNMT inhibition improved cardiac structure/function in a mouse HFpEF model, mitigated tubular senescence/fibrosis in CKD models, and mechanistic work connected NNMT to chemotherapy response; these are preclinical findings [pubmed:40484359; pubmed:41543936; pubmed:36622754].
• Are the published NNMT inhibitor chemotypes the same as 5‑Amino‑1MQ?
• No. The SAR series (bisubstrate and related high‑affinity inhibitors) are distinct chemotypes and should not be directly cross‑extrapolated to 5‑Amino‑1MQ [pubmed:29320176; pubmed:31589440; pubmed:37523719].
• Does a registry or patent entry validate 5‑Amino‑1MQ as a therapy?
• No. A PubChem listing is a registry record, and patent filings reflect intellectual property activity; neither is evidence of clinical efficacy or safety [pubchem:950107; patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].

References

• [pubmed:39067875] NAD(+) metabolism enzyme NNMT in cancer‑associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. https://pubmed.ncbi.nlm.nih.gov/39067875/
• [pubmed:40484359] Nicotinamide‑N‑methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model. https://pubmed.ncbi.nlm.nih.gov/40484359/
• [pubmed:41543936] NNMT inhibition counteracts tubular senescence and fibrosis in early stages of chronic kidney disease. https://pubmed.ncbi.nlm.nih.gov/41543936/
• [pubmed:34029690] Nicotinamide N‑methyl transferase (NNMT): An emerging therapeutic target. https://pubmed.ncbi.nlm.nih.gov/34029690/
• [pubmed:33453420] Nicotinamide N‑methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. https://pubmed.ncbi.nlm.nih.gov/33453420/
• [pubmed:37523719] Structure‑Activity Relationship Studies on Cell‑Potent Nicotinamide N‑Methyltransferase Bisubstrate Inhibitors. https://pubmed.ncbi.nlm.nih.gov/37523719/
• [pubmed:35756670] Nicotinamide N‑Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy. https://pubmed.ncbi.nlm.nih.gov/35756670/
• [pubmed:37576910] Nicotinamide N‑Methyl Transferase as a Predictive Marker of Tubular Fibrosis in CKD. https://pubmed.ncbi.nlm.nih.gov/37576910/
• [pubmed:29320176] Discovery of Bisubstrate Inhibitors of Nicotinamide N‑Methyltransferase (NNMT). https://pubmed.ncbi.nlm.nih.gov/29320176/
• [pubmed:36622754] N6‑Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N‑methyltransferase. https://pubmed.ncbi.nlm.nih.gov/36622754/
• [pubmed:31589440] High‑Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide N‑Methyltransferase (NNMT). https://pubmed.ncbi.nlm.nih.gov/31589440/
• [pubchem:950107] PubChem compound record: 5‑Amino‑1‑methylquinolinium. https://pubchem.ncbi.nlm.nih.gov/compound/950107
• [patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor] Google Patents search for 5‑Amino‑1MQ 5‑amino‑1‑methylquinolinium NNMT inhibitor. https://patents.google.com/?q=5-Amino-1MQ+5-amino-1-methylquinolinium+NNMT+inhibitor